The management of DS is inherently challenging as conventional antiepileptic drugs (AEDs) primarily aim to reduce seizure frequency rather than achieve elimination, a limitation rooted in the high prevalence of pharmacoresistance driven by SCN1A-mediated network hyperexcitability (de Lange et al., 2018; Wallace et al., 2016). Here, SCN1A is linked to Dravet syndrome.